Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses
- PMID: 27864902
- PMCID: PMC7167072
- DOI: 10.1002/jmv.24736
Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses
Abstract
A number of human coronaviruses (HCoVs) were reported in the last and present centuries. Some outbreaks of which (eg, SARS and MERS CoVs) caused the mortality of hundreds of people worldwide. The problem of finding a potent drug against HCoV strains lies in the inability of finding a drug that stops the viral replication through inhibiting its important proteins. In spite of its limited efficacy and potential side effects, Ribavirin is extensively used as a first choice against HCoVs. Therefore, scientists reverted towards the investigation of different drugs that can more specifically target proteins. In this study, four anti-HCV drugs (one approved by FDA and others under clinical trials) are tested against HCoV polymerases. Quantitative Structure-Activity Relationship (QSAR) and molecular docking are both used to compare the performance of the selected nucleotide inhibitors to their parent nucleotides and Ribavirin. Both QSAR and molecular docking showed that IDX-184 is superior compared to Ribavirin against MERS CoV, a result that was also reported for HCV. MK-0608 showed a performance that is comparable to Ribavirin. We strongly suggest an in vitro study on the potency of these two drugs against MERS CoV.
Keywords: HCV; QSAR; docking; human coronavirus; nucleotide inhibitor; polymerase.
© 2017 Wiley Periodicals, Inc.
Figures
Similar articles
-
Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.Mini Rev Med Chem. 2021;21(20):3191-3202. doi: 10.2174/1389557521666210225114733. Mini Rev Med Chem. 2021. PMID: 33632095 Review.
-
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.Life Sci. 2020 Jun 15;251:117627. doi: 10.1016/j.lfs.2020.117627. Epub 2020 Apr 3. Life Sci. 2020. PMID: 32251634 Free PMC article.
-
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.J Virol. 2016 Sep 12;90(19):8924-33. doi: 10.1128/JVI.01429-16. Print 2016 Oct 1. J Virol. 2016. PMID: 27466418 Free PMC article.
-
The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.Antiviral Res. 2015 Mar;115:21-38. doi: 10.1016/j.antiviral.2014.12.015. Epub 2014 Dec 29. Antiviral Res. 2015. PMID: 25554382 Free PMC article. Review.
-
Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.J Virol. 2005 Jun;79(11):7095-103. doi: 10.1128/JVI.79.11.7095-7103.2005. J Virol. 2005. PMID: 15890949 Free PMC article.
Cited by
-
A systematic review of RdRp of SARS-CoV-2 through artificial intelligence and machine learning utilizing structure-based drug design strategy.Turk J Chem. 2021 Dec 27;46(3):583-594. doi: 10.55730/1300-0527.3355. eCollection 2022. Turk J Chem. 2021. PMID: 37720604 Free PMC article. Review.
-
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.J Med Chem. 2023 Mar 23;66(6):3664-3702. doi: 10.1021/acs.jmedchem.2c01229. Epub 2023 Mar 1. J Med Chem. 2023. PMID: 36857133 Free PMC article. Review.
-
Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.Int J Mol Sci. 2022 Nov 18;23(22):14340. doi: 10.3390/ijms232214340. Int J Mol Sci. 2022. PMID: 36430817 Free PMC article. Review.
-
Current Treatments for COVID-19: Application of Supercritical Fluids in the Manufacturing of Oral and Pulmonary Formulations.Pharmaceutics. 2022 Nov 4;14(11):2380. doi: 10.3390/pharmaceutics14112380. Pharmaceutics. 2022. PMID: 36365198 Free PMC article. Review.
-
Deciphering inhibitory mechanism of coronavirus replication through host miRNAs-RNA-dependent RNA polymerase interactome.Front Genet. 2022 Aug 26;13:973252. doi: 10.3389/fgene.2022.973252. eCollection 2022. Front Genet. 2022. PMID: 36092931 Free PMC article.
References
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. 2012. Isolation of a novel Coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 367:1814–1820. - PubMed
-
- Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, Poon LL. 2003. Isolation and characterization of viruses related to the SARS Coronavirus from animals in southern China. Science. 302:276–278. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous